This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

43/100

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Background Blood-brain barrier (BBB) dysfunction is emerging as an important pathophysiologic factor in Alzheimer disease (AD). Cerebrospinal fluid (CSF) platelet-derived growth factor receptor-β (PDGFRβ) is a biomarker of BBB pericyte injury and has been implicated in cognitive impairment and AD. Methods We aimed to study CSF PDGFRβ protein levels, along with CSF biomarkers of brain amyloidosis and tau pathology in a well-characterized population of cognitively unimpaired individuals and correlated CSF findings with amyloid-PET positivity. We performed an institutional review board (IRB)-approved cross-sectional analysis of a prospectively enrolled cohort of 36 cognitively normal volunteers with available CSF, Pittsburgh compound B PET/CT, Mini-Mental State Exam score, Global Deterioration Scale, and known apolipoprotein E ( APOE ) ε4 status. Results Thirty-six subjects were included. Mean age was 63.3 years; 31 of 36 were female, 6 of 36 were amyloid-PET-positive and 12 of 36 were APOE ε4 carriers. We found a moderate positive correlation between CSF PDGFRβ and both total Tau (r=0.45, P =0.006) and phosphorylated Tau 181 (r=0.51, P =0.002). CSF PDGFRβ levels were not associated with either the CSF Aβ42 or the amyloid-PET. Conclusions We demonstrated a moderate positive correlation between PDGFRβ and both total Tau and phosphorylated Tau 181 in cognitively normal individuals. Our data support the hypothesis that BBB dysfunction represents an important early pathophysiologic step in AD, warranting larger prospective studies. Trial registration ClinicalTrials.gov Identifier: NCT00094939.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Haghdel, A., Smith, N., Glodzik, L., Li, Y., Wang, X., Crowder, T., et al. (2024). Evidence of Pericyte Damage in a Cognitively Normal Cohort: Association With CSF and PET Biomarkers of Alzheimer Disease. Alzheimer disease and associated disorders. https://doi.org/10.1097/wad.0000000000000623

Vancouver

Haghdel A, Smith N, Glodzik L, Li Y, Wang X, Crowder T, et al. Evidence of Pericyte Damage in a Cognitively Normal Cohort: Association With CSF and PET Biomarkers of Alzheimer Disease. Alzheimer disease and associated disorders. 2024. doi:10.1097/wad.0000000000000623. PMID: 38752577.

BibTeX

@article{haghdel2024-38752577,
  author  = {Haghdel, A. and Smith, N. and Glodzik, L. and Li, Y. and Wang, X. and Crowder, T. and Zhu, Y. S. and Butler, T. and others},
  title   = {{Evidence of Pericyte Damage in a Cognitively Normal Cohort: Association With CSF and PET Biomarkers of Alzheimer Disease}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2024},
  doi     = {10.1097/wad.0000000000000623},
  pmid    = {38752577},
  url     = {https://doi.org/10.1097/wad.0000000000000623}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Results Thirty-six subjects were included.
We found a moderate positive correlation between CSF PDGFRβ and both total Tau (r=0.45, P =0.006) and phosphorylated Tau 181 (r=0.51, P =0.002).
CSF PDGFRβ levels were not associated with either the CSF Aβ42 or the amyloid-PET.
Conclusions We demonstrated a moderate positive correlation between PDGFRβ and both total Tau and phosphorylated Tau 181 in cognitively normal individuals.

Why it matters

In 36 cognitively normal volunteers, higher CSF PDGFRβ, a marker of pericyte injury, correlated with higher total tau and phosphorylated tau 181 but not with amyloid measures. This is a small cross-sectional biomarker study and does not test any treatment, cure or prevention.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designcross-sectional
Evidence strengthModerate

How this study scored 43/100

Published in a peer-reviewed journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer disease and associated disorders)
Journal's citation record	1 / 4	Alzheimer Disease & Associated Disorders: journal h-index 131 (OpenAlex, 2026-10-29)
Study design	4 / 12	A snapshot of people at one point in time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	2 / 7	Cited 12 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	3.0 citations a year over 4 year(s) since 2024
Impact for its field and year	2 / 6	Cited 2.9× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 1 other studies in this library
Still being cited	1 / 4	Cited 12 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	2 / 4	Last-listed author Jana Ivanidze: h-index 25 (OpenAlex, whole career)
Institution's track record	1 / 3	Weill Cornell Medicine: institution h-index 1,163 (OpenAlex)
Multicenter collaboration	1 / 3	OpenAlex lists 3 institution(s) in 2 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 38752577)
Free to read	0 / 2	Behind a paywall — scores zero
Total	43 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Biomarkers

Also tagged “cerebrospinal”

821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →